A chemist, she lent her expertise in drug research to ACT UP, an organization known for its street protests, and helped accelerate the approval of H.I.V. and AIDS treatments.
An older Iris Long with short gray hair, wearing a light blue turtleneck and smiling slightly.
Iris Long in 2013. When she first attended an ACT UP meeting in 1987, she didn’t know anyone with AIDS, but “the epidemic was getting so bad, and she thought she could help,” one activist said. “We were a bunch of downtown queers, and she came from a background that was totally different from us.”Credit… Edward Linsmier
Richard Sandomir
By Richard Sandomir
April 17, 2026, 3:56 p.m. ET
See more of our coverage in your search results.
Add The New York Times on Google
Iris Long, a chemist whose knowledge of the intricacies of pharmaceutical clinical trials and the Food and Drug Administration’s approval process made her a transformational figure in ACT UP, the militant political action group dedicated to ending the AIDS crisis, died on April 4 in Astoria, Queens. She was 92.
Michael Long, her husband of 55 years and only immediate survivor, confirmed her death, at a rehabilitation center. She lived in Astoria.
By 1987, when Dr. Long first attended a meeting of ACT UP, the AIDS Coalition to Unleash Power, she had retired from her work as an organic chemist. She was looking to help people directly, rather than in a laboratory. She was not politically active, didn’t know anyone with AIDS and wasn’t even sure she had ever met anyone who was gay.
“God, the epidemic was getting so bad, and she thought she could help,” Jim Eigo, a writer and leading ACT UP member who worked closely with Dr. Long, said in an interview. “We were a bunch of downtown queers, and she came from a background that was totally different from us. She brought her love to us.”
At that first meeting, Dr. Long realized that the activists needed a guide who was fluent in science to help them expedite the approval of drugs to treat AIDS and the H.I.V. virus that causes it.
“She was their scientific North Star,” Dr. Anthony S. Fauci, the former director of the National Institute of Allergy and Infectious Diseases, said in an interview. “She told them that if you’re going to interact with the scientific community, you’re going to have to understand the science.”
She tutored the activists on immunology and virology and schooled them in the intricacies of the Food and Drug Administration’s approval process and pharmaceutical research protocols. She set up what became ACT UP’s treatment and data committee, and with Mr. Eigo wrote memos to drug companies and government agencies suggesting programs that would benefit people with H.I.V. and AIDS.
Image
A black-and-white photo of men forming a line holding sheets printed with various messages.
ACT UP members protesting in New York in 1988. Although Dr. Long participated in some of the group’s protests, she was not among the activists who were arrested. Credit…Sara Krulwich/The New York Times
Her guidance, Mr. Eigo said, empowered key ACT UP members, including Mark Harrington, to communicate with researchers and officials at the F.D.A. and other government agencies on a more equal, and therefore less confrontational, footing.
“They became so expert,” said Peter Staley, a prominent member of ACT UP, “that I witnessed some shocking conversations between Mark Harrington and Fauci talking about his lab work, and Fauci would just look stunned by Mark’s questions.”
How The Times decides who gets an obituary. There is no formula, scoring system or checklist in determining the news value of a life. We investigate, research and ask around before settling on our subjects. If you know of someone who might be a candidate for a Times obituary, please suggest it here.
Learn more about our process.
Mr. Harrington said in an interview that Dr. Long “took much younger, nonscientific people into her world.”
“She was relentless, and very focused on getting good information to the people who needed it,” he said.
Dr. Long, Mr. Eigo and Garry Kleinman, another ACT UP member, made a presentation to New York University doctors who were conducting clinical trials for AIDS drugs. The meeting soon led the F.D.A. to adopt parallel drug trials — with the result that patients who had exhausted azidothymidine, or AZT, the first drug approved to treat AIDS, could now take another drug (initially ganciclovir) that had passed the agency’s safety trials even while it was still being tested for effectiveness.
On another front, Dr. Long filled a critical void by creating the AIDS Treatment Registry, a regularly updated list of where drug trials were being conducted at hospitals in New York City, so that those who needed treatment would know where to go.
Editors’ Picks
You’ve Heard of the Sky Couch. Get Ready for the Skynest.
Spice Up Your Cooking Skills With Help From Your Phone
Drew Barrymore and Pete Davidson List Homes in Westchester County
“No one knows how many drugs are being tested that could be used to treat the disease,” she told The New York Times in 1988. “What I have done is to find out the names of those doing research at various institutions. It’s hit and miss. I call the doctors, identifying myself as Dr. Long, and question them about what they are doing and what is going on in their institutions.”
She also documented how few women were in federally sponsored clinical trials for AIDS drugs. As of February 1990, there were just 546 women enrolled in the trials, compared with 8,263 men.
That was significant, she told The San Francisco Chronicle, because “the clinical trials are the only way you can get treatment.”
Dr. Long, who participated in some of ACT UP’s protests but was not among the activists who were arrested, was named one of Glamour magazine’s 12 most inspiring women of 1989.
Iris Lillian Doerr was born on Dec. 8, 1933, in Manhattan. Her father, Henry, owned a butcher shop, and her mother, Lillian (Wildberger) Doerr, helped out in the store and briefly owned a dry-cleaning business.
Advertisement
SKIP ADVERTISEMENT
A high school chemistry course inspired Dr. Long to study the subject at Hunter College, where she earned bachelor’s and master’s degrees in 1955 and 1964. In 1972, she earned a Ph.D. in organic chemistry from the University of Connecticut. She went on to work at Memorial Sloan Kettering Cancer Center, Long Island Jewish Medical Center and Stony Brook University.
By the time she showed up at the ACT UP meeting, Dr. Long had already begun volunteering at Gay Men’s Health Crisis (now GMHC), the nonprofit dedicated to eliminating AIDS.
Image
An older Dr. Long with short, gray hair, standing outside with her arms crossed.
Glamour magazine named Dr. Long one of the 12 most inspiring women of 1989.Credit… Edward Linsmier
“With her suburban bob, she cut a figure that might have been perfectly ordinary on the subway, but not in this room, packed with fashion-conscious men and women,” David France wrote in “How to Survive a Plague: The Story of How Activists and Scientists Tamed AIDS” (2016). “Everything about her pointed to the fact that she was a working-class, middle-aged heterosexual woman — a platypus among the swans.”
But Dr. Long knew that her background could be useful to the group. Her research had focused on a class of antiretroviral drugs called nucleoside analogues — altered sugar molecules trained to lure diseased cells away from healthy cells — of which AZT was one.